Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects

References

• Trenkwalder C, Paulus W. Restless legs syndrome: pathophysiology, clinical presentation and management. Nat Rev Neurol. 2010;6:337–346.
   PubMed Web of Science ®Google Scholar
• International Restless Legs Study Group. IRLSSG diagnostic criteria for RLS. 2012 [cited 2016 Apr 25]. Available from: http://irlssg.org/diagnostic-criteria/
   Google Scholar
• Montplaisir J, Boucher S, Poirier G, et al. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–65.
   PubMed Web of Science ®Google Scholar
• Allen R, Walters A, Montplaisir J, et al. Restless legs syndrome prevalence and impact, REST general population study. Arch Intern Med. 2005;165:1286–1292.
   PubMed Web of Science ®Google Scholar
• Allen RP, Picchietti DL, Garcia-Borreguero D, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria–history, rationale, description, and significance. Sleep Med. 2014;15:860–873.
   PubMed Web of Science ®Google Scholar
• Ohayon MM, O’Hara R, Vitiello MV. Epidemiology of restless legs syndrome: a synthesis of the literature. Sleep Med Rev. 2012;16:283–295.
   PubMed Web of Science ®Google Scholar
• Bassetti C, Mauerhofer D, Gugger M, et al. Restless legs syndrome: a clinical study of 55 patients. Eur Neurol. 2001;45:67–74.
   PubMed Web of Science ®Google Scholar
• Earley CJ, Connor JR, Beard JL, et al. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. Neurology. 2000;54:1698–1700.
   PubMed Web of Science ®Google Scholar
• Gigli GL, Adorati M, Dolso P, et al. Restless legs syndrome in end-stage renal disease. Sleep Med. 2004;5:309–315.
   PubMed Web of Science ®Google Scholar
• Merlino G, Fratticci L, Valente M, et al. Association of restless legs syndrome in type 2 diabetes: a case-control study. Sleep. 2007;30:866–871.
   PubMed Web of Science ®Google Scholar
• Manconi M, Ferini-Strambi L, Filippi M, et al. Multicenter case-control study on restless legs syndrome in multiple sclerosis: the REMS study. Sleep. 2008;31:944–952.
   PubMed Web of Science ®Google Scholar
• Manconi M, Govoni V, De Vito A, et al. Restless legs syndrome and pregnancy. Neurology. 2004;63:1065–1069.
   PubMed Web of Science ®Google Scholar
• O’Keeffe ST. Secondary causes of restless legs syndrome in older people. Age Ageing. 2005;34:349–352.
   PubMed Web of Science ®Google Scholar
• Hening W. The clinical neurophysiology of the restless legs syndrome and periodic limb movements. Part I: diagnosis, assessment, and characterization. Clin Neurophysiol. 2004;115:1965–1974.
   PubMed Web of Science ®Google Scholar
• Buchfuhrer MJ. Strategies for the treatment of restless legs syndrome. Neurotherapeutics. 2012;9:776–790.
   PubMed Web of Science ®Google Scholar
• de Biase S, Valente M, Gigli GL. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone. Neuropsychiatr Dis Treat. 2016;12:417–425.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Allen RP, Kohnen R, et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine-International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med. 2007;8:520–530.
   PubMed Web of Science ®Google Scholar
• García-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med. 2016;21:1–11.
   PubMed Web of Science ®Google Scholar
• Garcia-Borreguero D, Kohnen R, Silber MH, et al. The long-term treatment of restless legs syndrome/Willis-Ekbom disease: evidence-based guidelines and clinical consensus best practice guidance: a report from the International Restless Legs Syndrome Study Group. Sleep Med. 2013;14:675–684.
   PubMed Web of Science ®Google Scholar
• Ferini-Strambi L, Marelli S. Pharmacotherapy for restless legs syndrome. Expert Opin Pharmacother. 2014;15:1127–1138.
   PubMed Web of Science ®Google Scholar
• Trenkwalder C, Beneš H, Grote L, et al. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension. Lancet Neurol. 2013;12:1141–1150.
   PubMed Web of Science ®Google Scholar
• Mundipharma receives positive European Commission decision on Targin® (oxycodone/naloxone) for the treatment of Restless Legs Syndrome [ cited 2016 Apr 25]. Available from: http://www.mundipharma.com/docs/default-source/press-releases-library/targin-rls-ec-positive.pdf?sfvrsn=0/
   Google Scholar
• Söderberg Löfdal KC, Andersson ML, Gustafsson LL. Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications. Drugs. 2013;73:533–543.
   PubMed Web of Science ®Google Scholar
• Choi YS, Billings JA. Opioid antagonists: a review of their role in palliative care, focusing on use in opioid-related constipation. J Pain Symptom Manage. 2002;24:71–90.
   PubMed Web of Science ®Google Scholar
• Reimer K, Hopp M, Zenz MG, et al. Meeting the challenges of opioid-induced constipation in chronic pain management – a novel approach. Pharmacology. 2009;83:10–17.
   PubMed Web of Science ®Google Scholar
• Meissner W, Schmidt U, Hartmann M, et al. Oral naloxone reverses opioid-associated constipation. Pain. 2000;84:105–109.
   PubMed Web of Science ®Google Scholar
• Kalso E. Oxycodone. J Pain Symptom Manage. 2005;29:S47–56.
   PubMed Web of Science ®Google Scholar
• Mandema JW, Kaiko RF, Oshlack B, et al. Characterization and validation of a pharmacokinetic model for controlled-release oxycodone. Br J Clin Pharmacol. 1996;42:747–756.
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Mattia C. Oxycodone. Pharmacological profile and clinical data in chronic pain management. Minerva Anestesiol. 2005;71:451–460.
   PubMedGoogle Scholar
• Smith K, Hopp M, Mundin G, et al. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged release combination in healthy adult volunteers. Clin Ther. 2008;30:2051–2068.
   PubMed Web of Science ®Google Scholar
• Leow KP, Wright AWE, Cramond T, et al. Determination of the serum protein binding of oxycodone and morphine using ultrafiltration. Ther Drug Monit. 1993;15:440–447.
   PubMed Web of Science ®Google Scholar
• Product monograph ^NTargin® [ cited 2016 Apr 25]. Available from: http://www.purdue.ca/files/2014-08-05_Targin-pm-mktg-eng.pdf
   Google Scholar
• Andreassen TN, Klepstad P, Davies A, et al. Influences on the pharmacokinetics of oxycodone: a multicentre cross-sectional study in 439 adult cancer patients. Eur J Clin Pharmacol. 2011;67:493–506.
   PubMed Web of Science ®Google Scholar
• Lalovic B, Kharasch E, Hoffer C, et al. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites. Clin Pharmacol Ther. 2006;79:461–479.
   PubMed Web of Science ®Google Scholar
• Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84:613–624.
   PubMed Web of Science ®Google Scholar
• Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract. 2007;7:352–356.
   PubMedGoogle Scholar
• Leppert W. Role of oxycodone and oxycodone/naloxone in cancer pain management. Pharmacol Rep. 2010;62:578–591.
   PubMed Web of Science ®Google Scholar
• Lugo RA, Kern SE. The pharmacokinetics of oxycodone. J Pain Palliat Care Pharmacother. 2004;18:17–30.
   PubMedGoogle Scholar
• Saari TI, Ihmsen H, Neuvonen PJ, et al. Oxycodone clearance is markedly reduced with advancing age: a population pharmacokinetic study. Br J Anaesth. 2012;108:491–498.
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain. 2009;13:56–64.
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother. 2009;10:531–543.
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Lux EA, et al. Efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of moderate/severe chronic non-malignant pain: results of a prospectively designed pooled analysis of two randomised, double-blind clinical trials. BMC Clin Pharmacol. 2010;10:1–9.
   PubMedGoogle Scholar
• Nadstawek J, Leyendecker P, Hopp M, et al. Patient assessment of a novel therapeutic approach for the treatment of severe, chronic pain. Int J Clin Pract. 2008;62:1159–1167.
   PubMed Web of Science ®Google Scholar
• Walters AS, Wagner ML, Hening WA, et al. Successful treatment of the idiopathic restless legs syndrome in a randomized double-blind trial of oxycodone versus placebo. Sleep. 1993;16:327–332.
   PubMed Web of Science ®Google Scholar
• Frampton JE. Oxycodone/Naloxone PR: a review in severe refractory restless legs syndrome. CNS Drugs. 2015;29:511–518.
   PubMed Web of Science ®Google Scholar
• Kreek MJ. Introduction to addictive disorders: implications for pharmacotherapies. In: Sibley DR, Hanin I, Kuhar M, et al., editors. Handbook of contemporary neuropharmacology. Hoboken (NJ): Wiley; 2007. p. 451–463.
   Google Scholar
• Bart G, Lenz S, Straka RJ, et al. Ethnic and genetic factors in methadone pharmacokinetics: a population pharmacokinetic study. Drug Alcohol Depend. 2014;145:185–193.
   PubMed Web of Science ®Google Scholar
• Product monograph ^NMETADOL^® [ cited 2016 Apr 25]. Available from: http://www.paladin-labs.com/our_products/PM_Metadol_EN.pdf?ver=11
   Google Scholar
• Ferrari A, Coccia CP, Bertolini A, et al. Methadone–metabolism, pharmacokinetics and interactions. Pharmacol Res. 2004;50:551–559.
   PubMed Web of Science ®Google Scholar
• Lugo RA, Satterfield KL, Kern SE. Pharmacokinetics of methadone. J Pain Palliat Care Pharmacother. 2005;19:13–24.
   PubMedGoogle Scholar
• Overholser BR, Foster DR. Opioid pharmacokinetic drug-drug interactions. Am J Manag Care. 2011;17 Suppl 11:S276–S287.
   PubMedGoogle Scholar
• Kharasch ED, Regina KJ, Blood J, et al. Methadone pharmacogenetics: CYP2B6 polymorphisms determine plasma concentrations, clearance, and metabolism. Anesthesiology. 2015;123:1142–1153.
   PubMed Web of Science ®Google Scholar
• Leppert W. The role of methadone in cancer pain treatment–a review. Int J Clin Pract. 2009;63:1095–1109.
   PubMed Web of Science ®Google Scholar
• Opdal MS, Arnesen M, Müller LD, et al. Effects of hemodialysis on methadone pharmacokinetics and QTc. Clin Ther. 2015;37:1594–1599.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Stubbert K. Role of cytochrome P4502B6 in methadone metabolism and clearance. J Clin Pharmacol. 2013;53:305–313.
   PubMed Web of Science ®Google Scholar
• Silver N, Allen RP, Senerth J, et al. A 10-year, longitudinal assessment of dopamine agonists and methadone in the treatment of restless legs syndrome. Sleep Med. 2011;12:440–444.
   PubMed Web of Science ®Google Scholar
• Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20:345–348.
   PubMed Web of Science ®Google Scholar
• Fanoe S, Jensen GB, Sjøgren P, et al. Oxycodone is associated with dose-dependent QTc prolongation in patients and low-affinity inhibiting of hERG activity in vitro. Br J Clin Pharmacol. 2009;67:172–179.
   PubMed Web of Science ®Google Scholar
• Sverrisdóttir E, Lund TM, Olesen AE, et al. A review of morphine and morphine-6-glucuronide’s pharmacokinetic-pharmacodynamic relationships in experimental and clinical pain. Eur J Pharm Sci. 2015;74:45–62.
   PubMed Web of Science ®Google Scholar
• Christrup LL. Morphine metabolites. Acta Anaesthesiol Scand. 1997;41:116–122.
   PubMed Web of Science ®Google Scholar
• Säwe J. High-dose morphine and methadone in cancer patients, clinical pharmacokinetic considerations of oral treatment. Clin Pharmacokin. 1986;11:87–106.
   PubMed Web of Science ®Google Scholar
• Collins SL, Faura CC, Moore RA, et al. Peak plasma concentrations after oral morphine: a systematic review. J Pain Symptom Manage. 1998;16:388–402.
   PubMed Web of Science ®Google Scholar
• Ederoth P, Tunblad K, Bouw R, et al. Blood-brain barrier transport of morphine in patients with severe brain trauma. Br J Clin Pharmacol. 2004;57:427–435.
   PubMed Web of Science ®Google Scholar
• Armstrong SC, Cozza KL. Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I. Psychosomatics. 2003;44:167–171.
   PubMed Web of Science ®Google Scholar
• Kilpatrick GJ, Smith TW. Morphine-6-glucuronide: actions and mechanisms. Med Res Rev. 2005;25:521–544.
   PubMed Web of Science ®Google Scholar
• Wright AW, Mather LE, Smith MT. Hydromorphone-3-glucuronide: a more potent neuro-excitant than its structural analogue, morphine-3-glucuronide. Life Sci. 2001;69:409–420.
   PubMed Web of Science ®Google Scholar
• Milne RW, Nation RL, Somogyi AA, et al. The influence of renal function on the renal clearance of morphine and its glucuronide metabolites in intensive-care patients. Br J Clin Pharmacol. 1992;34:53–59.
   PubMed Web of Science ®Google Scholar
• Product monograph ^NSANDOZ MORPHINE SR [ cited 2016 Apr 25] Available from: http://www.sandoz.ca/cs/groups/public/@sge_ca_sandoz/documents/document/n_prod_997055.pdf
   Google Scholar
• De Gregori S, Minella CE, De Gregori M, et al. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain. Ther Drug Monit. 2014;36:335–344.
   PubMed Web of Science ®Google Scholar
• Lindvall P, Ruuth K, Jakobsson B, et al. Intrathecal morphine as a treatment for refractory restless legs syndrome. Neurosurgery. 2008;63:E1209.
   Google Scholar
• Jakobsson B, Ruuth K. Successful treatment of restless legs syndrome with an implanted pump for intrathecal drug delivery. Acta Anaesthesiol Scand. 2002;46:114–117.
   PubMed Web of Science ®Google Scholar
• Ross DA, Narus MS, Nutt JG. Control of medically refractory restless legs syndrome with intrathecal morphine: case report. Neurosurgery. 2008;62:E263.
   Google Scholar
• Lindvall P, Hariz GM, Blomstedt P. Overall self-perceived health in restless legs treated with intrathecal morphine. Acta Neurol Scand. 2013;127:268–273.
   PubMed Web of Science ®Google Scholar
• Hornyak M, Kaube H. Long-term treatment of a patient with severe restless legs syndrome using intrathecal morphine. Neurology. 2012;79:2361–2362.
   PubMed Web of Science ®Google Scholar
• Likar R, Wittels M, Molnar M, et al. Pharmacokinetic and pharmacodynamic properties of tramadol IR and SR in elderly patients: a prospective, age-group-controlled study. Clin Ther. 2006;28:2022–2039.
   PubMed Web of Science ®Google Scholar
• Bamigbade TA, Davidson C, Langford RM, et al. Actions of tramadol, its enantiomers and principal metabolite, O-desmethylTramadol, on serotonin (5-HT) efflux and uptake in the rat dorsal raphe nucleus. Br J Anaesth. 1997;79:352–356.
   PubMed Web of Science ®Google Scholar
• Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.
   PubMed Web of Science ®Google Scholar
• Lewis KS, Han NH. Tramadol: a new centrally acting analgesic. Am J Health Syst Pharm. 1997;54:643–652.
   PubMed Web of Science ®Google Scholar
• Bodalia B, McDonald CJ, Smith KJ, et al. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J Pain Symptom Manage. 2003;25:142–149.
   PubMed Web of Science ®Google Scholar
• Brvar N, Mateović-Rojnik T, Grabnar I. Population pharmacokinetic modelling of tramadol using inverse Gaussian function for the assessment of drug absorption from prolonged and immediate release formulations. Int J Pharm. 2014;473:170–178.
   PubMed Web of Science ®Google Scholar
• Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs. 1993;46:313–340.
   PubMed Web of Science ®Google Scholar
• Dooney NM, Sundararajan K, Ramkumar T. Pharmacokinetics of tramadol after subcutaneous administration in a critically ill population and in a healthy cohort. BMC Anesthesiol. 2014;14:33.
   PubMed Web of Science ®Google Scholar
• Kizilbash A, Ngô-Minh CT. Review of extended-release formulations of tramadol for the management of chronic non-cancer pain: focus on marketed formulations. J Pain Res. 2014;7:149–161.
   PubMed Web of Science ®Google Scholar
• Skinner-Robertson S, Fradette C, Bouchard S, et al. Pharmacokinetics of tramadol and O-desmethyltramadol enantiomers following administration of extended-release tablets to elderly and young subjects. Drugs Aging. 2015;32:1029–1043.
   PubMed Web of Science ®Google Scholar
• Product monograph Ralivia™ [ cited 2016 Apr 25]. Available from: http://shoppers-healthcare-portal-a88a1f4b.s3.amazonaws.com/AgilityUGC/24b255ed-3dce-440f-974c-9f9bc901b0b4/Ralivia_EN_PM00012418.PDF
   Google Scholar
• Lauerma H, Markkula J. Treatment of restless legs syndrome with tramadol: an open study. J Clin Psychiatry. 1999;60:241–244.
   PubMed Web of Science ®Google Scholar
• Vetrugno R, La Morgia C, D’Angelo R, et al. Augmentation of restless legs syndrome with long-term tramadol treatment. Mov Disord. 2007;22:424–427.
   PubMed Web of Science ®Google Scholar
• Earley CJ, Allen RP. Restless legs syndrome augmentation associated with tramadol. Sleep Med. 2006;7:592–593.
   PubMed Web of Science ®Google Scholar
• Allen RP, Chen C, Garcia-Borreguero D, et al. Comparison of pregabalin with pramipexole for restless legs syndrome. N Engl J Med. 2014;370:621–631.
   PubMed Web of Science ®Google Scholar
• Maestri M, Fulda S, Ferini-Strambi L, et al. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease. Sleep Med. 2014;15:570–575.
   PubMed Web of Science ®Google Scholar
• Ordóñez Gallego A, González Barón M, Espinosa Arranz E. Oxycodone: a pharmacological and clinical review. Clin Transl Oncol. 2007;9:298–307.
   PubMed Web of Science ®Google Scholar